Dier Mardi 4

What Happened
Dier Mardi, Executive Vice President and Chief Financial Officer of Madrigal Pharmaceuticals (MDGL), sold 1,982 shares in open-market transactions on March 6, 2026, generating total proceeds of approximately $853,991. On March 4, 2026, Mardi was granted 5,215 restricted stock units (RSUs) and a derivative award covering 6,519 shares (an option grant) — both reported as acquisitions (A) at $0.00. The sales were disposals (S) executed in multiple tranches at prices roughly between $425.08 and $437.65.

Key Details

• Transaction dates: Awards granted March 4, 2026; sales executed March 6, 2026; Form 4 filed March 6, 2026 (appears timely).
• Sales: 1,982 shares sold across multiple trades; prices ranged ~ $425.08–$437.65; proceeds ≈ $853,991.
• Awards: 5,215 RSUs (vest 25% each year on March 4, 2027–2030 per footnote F1); 6,519-option-type derivative with staged vesting beginning March 4, 2027 (per F12).
• Notable footnotes: Some sales were automatic to cover tax withholding on RSU vesting (F2); other sales were executed under a Rule 10b5-1 trading plan adopted Sept 2, 2025 (F3). Several reported sale prices are weighted averages covering small price ranges (F4–F11).
• Shares owned after the transactions are not included in the provided excerpt.

Context

• The March 4 entries are grants (A): RSUs and a time-based option grant that vest over multiple periods — these are compensation awards, not open-market purchases.
• The March 6 disposals include routine actions: tax-withholding sales and scheduled 10b5-1 plan trades. Such sales are common for executives and do not by themselves indicate management sentiment.
• Filing appears timely (filed March 6 for trades on March 4 and March 6); no late-filing flag reported in the provided data.